Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience.

Innocenti I, Morelli F, Autore F, Piciocchi A, Frustaci A, Mauro FR, Schiattone L, Trentin L, Del Poeta G, Reda G, Rigolin GM, Ibatici A, Ciolli S, Coscia M, Sportoletti P, Murru R, Levato L, Gentile M, D'Arena G, Efremov DG, Tedeschi A, Scarfò L, Cuneo A, Foà R, Laurenti L.

Br J Haematol. 2019 Jul 31. doi: 10.1111/bjh.16123. [Epub ahead of print] No abstract available.

PMID:
31364153
2.

GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations.

Sportoletti P, Celani L, Varasano E, Rossi R, Sorcini D, Rompietti C, Strozzini F, Del Papa B, Guarente V, Spinozzi G, Cecchini D, Bereshchenko O, Haferlach T, Martelli MP, Falzetti F, Falini B.

Leukemia. 2019 Jul;33(7):1827-1832. doi: 10.1038/s41375-019-0399-7. Epub 2019 Feb 12. No abstract available.

PMID:
30755706
3.

IL-4-dependent Jagged1 expression/processing is associated with survival of chronic lymphocytic leukemia cells but not with Notch activation.

De Falco F, Del Papa B, Baldoni S, Sabatini R, Falzetti F, Di Ianni M, Martelli MP, Mezzasoma F, Pelullo M, Marconi P, Sportoletti P, Screpanti I, Rosati E.

Cell Death Dis. 2018 Nov 26;9(12):1160. doi: 10.1038/s41419-018-1185-6.

4.

Uncommon lymphoplasmacytic lymphoma with IgA paraproteinemia: a challenging clinical diagnosis solved by MYD88 mutation analysis.

Martino G, Marra A, Ascani S, Sportoletti P.

Ann Hematol. 2019 Jun;98(6):1507-1508. doi: 10.1007/s00277-018-3545-9. Epub 2018 Nov 13. No abstract available.

PMID:
30426157
5.

Mutant NPM1 Maintains the Leukemic State through HOX Expression.

Brunetti L, Gundry MC, Sorcini D, Guzman AG, Huang YH, Ramabadran R, Gionfriddo I, Mezzasoma F, Milano F, Nabet B, Buckley DL, Kornblau SM, Lin CY, Sportoletti P, Martelli MP, Falini B, Goodell MA.

Cancer Cell. 2018 Sep 10;34(3):499-512.e9. doi: 10.1016/j.ccell.2018.08.005.

6.

NOTCH and Graft-Versus-Host Disease.

Di Ianni M, Del Papa B, Baldoni S, Di Tommaso A, Fabi B, Rosati E, Natale A, Santarone S, Olioso P, Papalinetti G, Giancola R, Accorsi P, Di Bartolomeo P, Sportoletti P, Falzetti F.

Front Immunol. 2018 Aug 10;9:1825. doi: 10.3389/fimmu.2018.01825. eCollection 2018. Review.

7.

NOTCH1 Aberrations in Chronic Lymphocytic Leukemia.

Rosati E, Baldoni S, De Falco F, Del Papa B, Dorillo E, Rompietti C, Albi E, Falzetti F, Di Ianni M, Sportoletti P.

Front Oncol. 2018 Jun 27;8:229. doi: 10.3389/fonc.2018.00229. eCollection 2018. Review.

8.

NOTCH1 Is Aberrantly Activated in Chronic Lymphocytic Leukemia Hematopoietic Stem Cells.

Di Ianni M, Baldoni S, Del Papa B, Aureli P, Dorillo E, De Falco F, Albi E, Varasano E, Di Tommaso A, Giancola R, Accorsi P, Rotta G, Rompietti C, Silva Barcelos EC, Campese AF, Di Bartolomeo P, Screpanti I, Rosati E, Falzetti F, Sportoletti P.

Front Oncol. 2018 Apr 20;8:105. doi: 10.3389/fonc.2018.00105. eCollection 2018.

9.

Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia.

Baldoni S, Del Papa B, Dorillo E, Aureli P, De Falco F, Rompietti C, Sorcini D, Varasano E, Cecchini D, Zei T, Di Tommaso A, Rosati E, Alexe G, Roti G, Stegmaier K, Di Ianni M, Falzetti F, Sportoletti P.

Int J Cancer. 2018 Aug 15;143(4):958-970. doi: 10.1002/ijc.31355. Epub 2018 Mar 23.

10.

Cytogenetic/mutation profile of chronic lymphocytic leukemia/malignant melanoma collision tumors of the skin.

La Starza R, Pierini T, Pastorino L, Albi E, Matteucci C, Crescenzi B, Sportoletti P, Covarelli P, Falzetti F, Roti G, Ascani S, Mecucci C.

Mol Cytogenet. 2018 Jan 16;11:6. doi: 10.1186/s13039-017-0353-1. eCollection 2018.

11.

A scale of "bad" co-mutations in NPM1-driven AML.

Falini B, Sportoletti P.

Blood. 2017 Oct 26;130(17):1877-1879. doi: 10.1182/blood-2017-09-804062. No abstract available.

12.

Wnt/β-Catenin Signaling Induces Integrin α4β1 in T Cells and Promotes a Progressive Neuroinflammatory Disease in Mice.

Sorcini D, Bruscoli S, Frammartino T, Cimino M, Mazzon E, Galuppo M, Bramanti P, Al-Banchaabouchi M, Farley D, Ermakova O, Britanova O, Izraelson M, Chudakov D, Biagioli M, Sportoletti P, Flamini S, Raspa M, Scavizzi F, Nerlov C, Migliorati G, Riccardi C, Bereshchenko O.

J Immunol. 2017 Nov 1;199(9):3031-3041. doi: 10.4049/jimmunol.1700247. Epub 2017 Sep 22.

13.

Clinical-Grade-Expanded Regulatory T Cells Prevent Graft-versus-Host Disease While Allowing a Powerful T Cell-Dependent Graft-versus-Leukemia Effect in Murine Models.

Del Papa B, Ruggeri L, Urbani E, Baldoni S, Cecchini D, Zei T, Iacucci Ostini R, Crescenzi B, Carotti A, Pierini A, Sportoletti P, Di Bartolomeo P, Falzetti F, Mecucci C, Velardi A, Martelli MF, Di Ianni M.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1847-1851. doi: 10.1016/j.bbmt.2017.07.009. Epub 2017 Jul 17.

14.

Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome.

Albi E, Baldoni S, Aureli P, Dorillo E, Del Papa B, Ascani S, Di Ianni M, Falzetti F, Sportoletti P.

Tumori. 2017 Nov 15;103(Suppl. 1):e37-e40. doi: 10.5301/tj.5000667.

PMID:
28708231
15.

The landscape of BRAF transcript and protein variants in human cancer.

Marranci A, Jiang Z, Vitiello M, Guzzolino E, Comelli L, Sarti S, Lubrano S, Franchin C, Echevarría-Vargas I, Tuccoli A, Mercatanti A, Evangelista M, Sportoletti P, Cozza G, Luzi E, Capobianco E, Villanueva J, Arrigoni G, Signore G, Rocchiccioli S, Pitto L, Tsinoremas N, Poliseno L.

Mol Cancer. 2017 Apr 28;16(1):85. doi: 10.1186/s12943-017-0645-4.

16.

A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis.

Moretti S, Renga G, Oikonomou V, Galosi C, Pariano M, Iannitti RG, Borghi M, Puccetti M, De Zuani M, Pucillo CE, Paolicelli G, Zelante T, Renauld JC, Bereshchenko O, Sportoletti P, Lucidi V, Russo MC, Colombo C, Fiscarelli E, Lass-Flörl C, Majo F, Ricciotti G, Ellemunter H, Ratclif L, Talesa VN, Napolioni V, Romani L.

Nat Commun. 2017 Jan 16;8:14017. doi: 10.1038/ncomms14017.

17.

The NOTCH1/CD39 axis: a Treg trip-switch for GvHD.

Del Papa B, Pierini A, Sportoletti P, Baldoni S, Cecchini D, Rosati E, Dorillo E, Aureli P, Zei T, Iacucci Ostini R, Ruggeri L, Carotti A, Velardi A, Negrin R, Martelli MF, Falzetti F, Di Ianni M.

Leukemia. 2016 Sep;30(9):1931-4. doi: 10.1038/leu.2016.87. Epub 2016 Apr 29. No abstract available.

PMID:
27125307
18.

Lack of glucocorticoid-induced leucine zipper (GILZ) deregulates B-cell survival and results in B-cell lymphocytosis in mice.

Bruscoli S, Biagioli M, Sorcini D, Frammartino T, Cimino M, Sportoletti P, Mazzon E, Bereshchenko O, Riccardi C.

Blood. 2015 Oct 8;126(15):1790-801. doi: 10.1182/blood-2015-03-631580. Epub 2015 Aug 14.

19.

Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL.

De Falco F, Sabatini R, Del Papa B, Falzetti F, Di Ianni M, Sportoletti P, Baldoni S, Screpanti I, Marconi P, Rosati E.

Oncotarget. 2015 Jun 30;6(18):16559-72.

20.

Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.

Falini B, Sportoletti P, Brunetti L, Martelli MP.

Br J Haematol. 2015 Aug;170(3):305-22. doi: 10.1111/bjh.13409. Epub 2015 Apr 19. Review.

PMID:
25891481
21.

Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells.

Martelli MP, Gionfriddo I, Mezzasoma F, Milano F, Pierangeli S, Mulas F, Pacini R, Tabarrini A, Pettirossi V, Rossi R, Vetro C, Brunetti L, Sportoletti P, Tiacci E, Di Raimondo F, Falini B.

Blood. 2015 May 28;125(22):3455-65. doi: 10.1182/blood-2014-11-611459. Epub 2015 Mar 20.

22.

A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells.

Guarnerio J, Riccardi L, Taulli R, Maeda T, Wang G, Hobbs RM, Song MS, Sportoletti P, Bernardi R, Bronson RT, Castillo-Martin M, Cordon-Cardo C, Lunardi A, Pandolfi PP.

Cancer Discov. 2015 Apr;5(4):396-409. doi: 10.1158/2159-8290.CD-14-1022. Epub 2015 Jan 22.

23.

BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.

Pettirossi V, Santi A, Imperi E, Russo G, Pucciarini A, Bigerna B, Schiavoni G, Fortini E, Spanhol-Rosseto A, Sportoletti P, Mannucci R, Martelli MP, Klein-Hitpass L, Falini B, Tiacci E.

Blood. 2015 Feb 19;125(8):1207-16. doi: 10.1182/blood-2014-10-603100. Epub 2014 Dec 5.

24.

Constitutive phosphorylation of the active Notch1 intracellular domain in chronic lymphocytic leukemia cells with NOTCH1 mutation.

De Falco F, Sabatini R, Falzetti F, Di Ianni M, Sportoletti P, Baldoni S, Del Papa B, Screpanti I, Marconi P, Rosati E.

Leukemia. 2015 Apr;29(4):994-8. doi: 10.1038/leu.2014.329. Epub 2014 Nov 26. No abstract available.

PMID:
25425197
25.

Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications.

Sportoletti P, Varasano E, Rossi R, Mupo A, Tiacci E, Vassiliou G, Martelli MP, Falini B.

Leukemia. 2015 Feb;29(2):269-78. doi: 10.1038/leu.2014.257. Epub 2014 Sep 2. Review.

PMID:
25179729
26.

A revised NOTCH1 mutation frequency still impacts survival while the allele burden predicts early progression in chronic lymphocytic leukemia.

Sportoletti P, Baldoni S, Del Papa B, Aureli P, Dorillo E, Ruggeri L, Plebani S, Amico V, Di Tommaso A, Rosati E, Marconi P, Di Ianni M, Falzetti F.

Leukemia. 2014 Feb;28(2):436-9. doi: 10.1038/leu.2013.289. Epub 2013 Oct 9. No abstract available.

PMID:
24177259
27.

NOTCH and NF-κB interplay in chronic lymphocytic leukemia is independent of genetic lesion.

Baldoni S, Sportoletti P, Del Papa B, Aureli P, Dorillo E, Rosati E, Ciurnelli R, Marconi P, Falzetti F, Di Ianni M.

Int J Hematol. 2013 Aug;98(2):153-7. doi: 10.1007/s12185-013-1368-y. Epub 2013 May 21.

PMID:
23690290
28.

A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice.

Mupo A, Celani L, Dovey O, Cooper JL, Grove C, Rad R, Sportoletti P, Falini B, Bradley A, Vassiliou GS.

Leukemia. 2013 Sep;27(9):1917-20. doi: 10.1038/leu.2013.77. Epub 2013 Mar 12. No abstract available.

29.

The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model.

Sportoletti P, Varasano E, Rossi R, Bereshchenko O, Cecchini D, Gionfriddo I, Bolli N, Tiacci E, Intermesoli T, Zanghì P, Masciulli A, Martelli MP, Falzetti F, Martelli MF, Falini B.

Blood. 2013 Apr 25;121(17):3447-58. doi: 10.1182/blood-2012-08-449553. Epub 2013 Feb 22.

30.

Mutational landscape of AML with normal cytogenetics: biological and clinical implications.

Martelli MP, Sportoletti P, Tiacci E, Martelli MF, Falini B.

Blood Rev. 2013 Jan;27(1):13-22. doi: 10.1016/j.blre.2012.11.001. Epub 2012 Dec 20. Review.

PMID:
23261068
31.

Notch1 modulates mesenchymal stem cells mediated regulatory T-cell induction.

Del Papa B, Sportoletti P, Cecchini D, Rosati E, Balucani C, Baldoni S, Fettucciari K, Marconi P, Martelli MF, Falzetti F, Di Ianni M.

Eur J Immunol. 2013 Jan;43(1):182-7. doi: 10.1002/eji.201242643. Epub 2012 Dec 5.

32.

A novel NOTCH1 PEST domain mutation in a case of chronic lymphocytic leukemia.

Sportoletti P, Baldoni S, Del Papa B, Cantaffa R, Ciurnelli R, Aureli P, Rosati E, Marconi P, Di Ianni M, Falzetti F.

Leuk Lymphoma. 2013 Aug;54(8):1780-2. doi: 10.3109/10428194.2012.749405. Epub 2012 Dec 10. No abstract available.

PMID:
23151304
33.

Up-regulation of translation eukaryotic initiation factor 4E in nucleophosmin 1 haploinsufficient cells results in changes in CCAAT enhancer-binding protein α activity: implications in myelodysplastic syndrome and acute myeloid leukemia.

Khanna-Gupta A, Abayasekara N, Levine M, Sun H, Virgilio M, Nia N, Halene S, Sportoletti P, Jeong JY, Pandolfi PP, Berliner N.

J Biol Chem. 2012 Sep 21;287(39):32728-37. Epub 2012 Jul 31.

34.

T regulatory cell separation for clinical application.

Di Ianni M, Del Papa B, Zei T, Iacucci Ostini R, Cecchini D, Cantelmi MG, Baldoni S, Sportoletti P, Cavalli L, Carotti A, Pierini A, Falini B, Martelli MF, Falzetti F.

Transfus Apher Sci. 2012 Oct;47(2):213-6. doi: 10.1016/j.transci.2012.06.007. Epub 2012 Jul 12. Review.

PMID:
22795999
35.

How does the NPM1 mutant induce leukemia?

Sportoletti P.

Pediatr Rep. 2011 Jun 22;3 Suppl 2:e6. doi: 10.4081/pr.2011.s2.e6.

36.

Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation.

Di Ianni M, Falzetti F, Carotti A, Terenzi A, Del Papa B, Perruccio K, Ruggeri L, Sportoletti P, Rosati E, Marconi P, Falini B, Reisner Y, Velardi A, Aversa F, Martelli MF.

Best Pract Res Clin Haematol. 2011 Sep;24(3):459-66. doi: 10.1016/j.beha.2011.05.005. Epub 2011 Jun 29.

PMID:
21925099
37.

BRAF mutations in hairy-cell leukemia.

Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, Sportoletti P, Pettirossi V, Mannucci R, Elliott O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, Foà R, Farinelli L, Haferlach T, Pasqualucci L, Rabadan R, Falini B.

N Engl J Med. 2011 Jun 16;364(24):2305-15. doi: 10.1056/NEJMoa1014209. Epub 2011 Jun 11.

38.

CD4(+) CD25(low) GITR(+) cells: a novel human CD4(+) T-cell population with regulatory activity.

Bianchini R, Bistoni O, Alunno A, Petrillo MG, Ronchetti S, Sportoletti P, Bocci EB, Nocentini G, Gerli R, Riccardi C.

Eur J Immunol. 2011 Aug;41(8):2269-78. doi: 10.1002/eji.201040943. Epub 2011 Jul 4.

39.

Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation.

Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, Del Papa B, Zei T, Ostini RI, Cecchini D, Aloisi T, Perruccio K, Ruggeri L, Balucani C, Pierini A, Sportoletti P, Aristei C, Falini B, Reisner Y, Velardi A, Aversa F, Martelli MF.

Blood. 2011 Apr 7;117(14):3921-8. doi: 10.1182/blood-2010-10-311894. Epub 2011 Feb 3.

40.

The glucocorticoid-induced TNF receptor family-related protein (GITR) is critical to the development of acute pancreatitis in mice.

Galuppo M, Nocentini G, Mazzon E, Ronchetti S, Esposito E, Riccardi L, Sportoletti P, Di Paola R, Bruscoli S, Riccardi C, Cuzzocrea S.

Br J Pharmacol. 2011 Mar;162(5):1186-201. doi: 10.1111/j.1476-5381.2010.01123.x.

41.

Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?

Falini B, Martelli MP, Bolli N, Sportoletti P, Liso A, Tiacci E, Haferlach T.

Blood. 2011 Jan 27;117(4):1109-20. doi: 10.1182/blood-2010-08-299990. Epub 2010 Oct 28. Review.

42.

Glucocorticoid-Induced TNFR family Related gene (GITR) enhances dendritic cell activity.

Ronchetti S, Nocentini G, Petrillo MG, Bianchini R, Sportoletti P, Bastianelli A, Ayroldi EM, Riccardi C.

Immunol Lett. 2011 Mar 30;135(1-2):24-33. doi: 10.1016/j.imlet.2010.09.008. Epub 2010 Sep 29.

PMID:
20883723
43.

NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL.

Sportoletti P, Baldoni S, Cavalli L, Del Papa B, Bonifacio E, Ciurnelli R, Bell AS, Di Tommaso A, Rosati E, Crescenzi B, Mecucci C, Screpanti I, Marconi P, Martelli MF, Di Ianni M, Falzetti F.

Br J Haematol. 2010 Nov;151(4):404-6. doi: 10.1111/j.1365-2141.2010.08368.x. Epub 2010 Aug 31. No abstract available.

PMID:
20813007
44.

Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation.

Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, Sportoletti P, Varmeh S, Egia A, Fedele G, Rameh L, Loda M, Pandolfi PP.

Sci Signal. 2010 Apr 13;3(117):ra29. doi: 10.1126/scisignal.2000594. Erratum in: Sci Signal. 2010;3(123):er6.

45.

Morgana/chp-1, a ROCK inhibitor involved in centrosome duplication and tumorigenesis.

Ferretti R, Palumbo V, Di Savino A, Velasco S, Sbroggiò M, Sportoletti P, Micale L, Turco E, Silengo L, Palumbo G, Hirsch E, Teruya-Feldstein J, Bonaccorsi S, Pandolfi PP, Gatti M, Tarone G, Brancaccio M.

Dev Cell. 2010 Mar 16;18(3):486-95. doi: 10.1016/j.devcel.2009.12.020.

46.

Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives.

Falini B, Sportoletti P, Martelli MP.

Curr Opin Oncol. 2009 Nov;21(6):573-81. doi: 10.1097/CCO.0b013e3283313dfa. Review.

PMID:
19770764
47.

The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model.

Cheng K, Sportoletti P, Ito K, Clohessy JG, Teruya-Feldstein J, Kutok JL, Pandolfi PP.

Blood. 2010 Apr 22;115(16):3341-5. doi: 10.1182/blood-2009-03-208587. Epub 2009 Aug 7.

48.

Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo.

Di Ianni M, Moretti L, Terenzi A, Bazzucchi F, Del Papa B, Bazzucchi M, Ciurnelli R, Lucchesi A, Sportoletti P, Rosati E, Marconi PF, Falzetti F, Tabilio A.

Cytotherapy. 2009;11(1):86-96. doi: 10.1080/14653240802666035.

PMID:
19153855
49.

Mesenchymal cells recruit and regulate T regulatory cells.

Di Ianni M, Del Papa B, De Ioanni M, Moretti L, Bonifacio E, Cecchini D, Sportoletti P, Falzetti F, Tabilio A.

Exp Hematol. 2008 Mar;36(3):309-18. doi: 10.1016/j.exphem.2007.11.007.

PMID:
18279718
50.

Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse.

Sportoletti P, Grisendi S, Majid SM, Cheng K, Clohessy JG, Viale A, Teruya-Feldstein J, Pandolfi PP.

Blood. 2008 Apr 1;111(7):3859-62. doi: 10.1182/blood-2007-06-098251. Epub 2008 Jan 22.

Supplemental Content

Loading ...
Support Center